تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $3.3B | $3.1B | $2.9B | $3.0B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.4B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B | $913M |
| سود ناخالص | $1.2B | $1.1B | $1.0B | $1.1B | $1.1B | $1.2B | $768M | $609M | $546M | $513M | $501M | $456M | $448M | $435M | $388M | $339M | $318M | $304M | $303M | $292M | $262M |
| حاشیه سود ناخالص % | 36.8% | 35.9% | 34.6% | 38.4% | 39.5% | 41.4% | 35.8% | 33.0% | 31.8% | 32.1% | 33.2% | 32.6% | 31.5% | 31.8% | 30.6% | 28.4% | 28.7% | 28.8% | 28.8% | 28.6% | 28.7% |
| سود عملیاتی (EBIT) | $700M | $617M | $595M | $711M | $764M | $759M | $419M | $297M | $255M | $229M | $197M | $129M | $182M | $162M | $136M | $116M | $106M | $106M | $125M | $113M | $106M |
| حاشیه سود عملیاتی % | 21.1% | 20.1% | 20.6% | 24.1% | 26.5% | 26.8% | 19.5% | 16.1% | 14.8% | 14.3% | 13.0% | 9.2% | 12.8% | 11.9% | 10.8% | 9.7% | 9.6% | 10.0% | 11.8% | 11.1% | 11.6% |
| سود خالص | $565M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M | $96M | $127M | $112M | $81M | $76M | $65M | $73M | $86M | $71M | $67M |
| حاشیه سود خالص % | 17.0% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% | 6.8% | 8.9% | 8.2% | 6.4% | 6.3% | 5.9% | 6.9% | 8.2% | 6.9% | 7.3% |
| EBITDA | — | $724M | $744M | $844M | $808M | $880M | $519M | $403M | $353M | $326M | $288M | $218M | $272M | $248M | $200M | $183M | $161M | $166M | $186M | $158M | $150M |
| سود هر سهم (EPS) | $7.82 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.12 | $1.02 | $0.89 | $1.00 | $1.19 | $0.98 | $1.00 |
| سهام منتشرشده (میلیون) | — | 73M | 74M | 75M | 76M | 76M | 76M | 75M | 75M | 76M | 75M | 74M | 73M | 71M | 72M | 74M | 73M | 73M | 72M | 72M | 67M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی WST در دسترس است. /companies/us/WST
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms